Revisiting AXL as a therapeutic target in soft tissue sarcoma: dubermatinib and bemcentinib effects are largely independent of AXL inhibition
- 1Spanish National Research Council
Abstract
Soft tissue sarcomas (STS) are a heterogeneous group of mesenchymal malignancies with generally poor prognosis, raising a continued interest in novel therapeutic targets. The TAM-family receptor tyrosine kinase AXL has been proposed as a therapeutic target across several cancer types, including STS. Here we revisit the clinical relevance of AXL in STS by combining in silico analyses with functional and transcriptomic characterisation of two AXL inhibitors, dubermatinib and bemcentinib, in HT-1080 and SK-LMS-1 cells. STS ranked among the tumour types with the highest median AXL mRNA expression across The Cancer Genome Atlas, yet AXL expression was not associated with patient survival. Both inhibitors reduced cell viability and induced apoptosis but, unexpectedly, shRNA-mediated AXL knockdown didn't reproduce their antiproliferative effect nor modified sensitivity to either drug. Transcriptomic profiling showed weak correlation between knockdown- and drug-induced changes, with most drug-regulated genes being AXL-independent and largely cell line-specific. Connectivity analysis against LINCS, regulatory-network inference and CRISPR dependency data instead point to mitotic and PI3K-mTOR pathways as candidate mediators of the therapeutic activity. Thus, dubermatinib and bemcentinib show antitumour activity in STS models that is largely independent of AXL inhibition, suggesting that the rationale for AXL-directed therapy may be reconsidered.
Related
- Dual inhibition of p38α MAPK and Casein kinase δ/ϵ as a novel treatment strategy for AR-independent and taxane-resistant advanced prostate cancer
- Lipoprotein(a) Inhibition: Current Evidence, Therapeutic Landscape, and Future Directions
- Choline Kinase Alpha Inhibition is a Mutation Agnostic Therapeutic Vulnerability in Clonal Hematopoiesis
- Tarloxotinib targets tumor hypoxia to improve therapeutic efficacy of immune checkpoint inhibition in a MyD88-dependent manner.
- Perk mediates tumor cell fate and therapeutic outcome in response to CDK4/6 inhibition
BibTeX
@misc{garnesgarcia2026revisiting,
title = {{Revisiting AXL as a therapeutic target in soft tissue sarcoma: dubermatinib and bemcentinib effects are largely independent of AXL inhibition}},
author = {C. Garnes-Garcia and P. Fernandez-Aroca and F. J. Cimas and M. J. Ruiz-Hidalgo and B. Belandia and N. Mayor-Garnacho and A. Fernandez-Aramburo and V. J. Sanchez-Arevalo Lobo and R. Sanchez-Prieto and D. M. Fernandez-Aroca},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.02.755908},
url = {https://www.biorxiv.org/content/10.64898/2026.10.02.755908v1},
note = {CC BY-NC},
}
RIS
TY - UNPB
TI - Revisiting AXL as a therapeutic target in soft tissue sarcoma: dubermatinib and bemcentinib effects are largely independent of AXL inhibition
AU - C. Garnes-Garcia
AU - P. Fernandez-Aroca
AU - F. J. Cimas
AU - M. J. Ruiz-Hidalgo
AU - B. Belandia
AU - N. Mayor-Garnacho
AU - A. Fernandez-Aramburo
AU - V. J. Sanchez-Arevalo Lobo
AU - R. Sanchez-Prieto
AU - D. M. Fernandez-Aroca
PY - 2026
DA - 2026/10/02
PB - bioRxiv
DO - 10.64898/2026.10.02.755908
UR - https://www.biorxiv.org/content/10.64898/2026.10.02.755908v1
AB - Soft tissue sarcomas (STS) are a heterogeneous group of mesenchymal malignancies with generally poor prognosis, raising a continued interest in novel therapeutic targets. The TAM-family receptor tyrosine kinase AXL has been proposed as a therapeutic target across several cancer types, including STS. Here we revisit the clinical relevance of AXL in STS by combining in silico analyses with functional and transcriptomic characterisation of two AXL inhibitors, dubermatinib and bemcentinib, in HT-1080 and SK-LMS-1 cells. STS ranked among the tumour types with the highest median AXL mRNA expression across The Cancer Genome Atlas, yet AXL expression was not associated with patient survival. Both inhibitors reduced cell viability and induced apoptosis but, unexpectedly, shRNA-mediated AXL knockdown didn't reproduce their antiproliferative effect nor modified sensitivity to either drug. Transcriptomic profiling showed weak correlation between knockdown- and drug-induced changes, with most drug-regulated genes being AXL-independent and largely cell line-specific. Connectivity analysis against LINCS, regulatory-network inference and CRISPR dependency data instead point to mitotic and PI3K-mTOR pathways as candidate mediators of the therapeutic activity. Thus, dubermatinib and bemcentinib show antitumour activity in STS models that is largely independent of AXL inhibition, suggesting that the rationale for AXL-directed therapy may be reconsidered.
ER -